Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinrAIR-Sclrodermie study

被引:140
作者
Hachulla, Eric [1 ]
Carpentier, Patrick [10 ]
Gressin, Virginie [12 ]
Diot, Elisabeth [13 ]
Allanore, Yannick [9 ]
Sibilia, Jean [11 ]
Launay, David
Mouthon, Luc [9 ]
Jego, Patrick [8 ]
Cabane, Jean [7 ]
de Groote, Pascal [6 ]
Chabrol, Amelie [5 ]
Lazareth, Isabelle [4 ]
Guillevin, Loic [9 ]
Clerson, Pierre [3 ]
Humbert, Marc [2 ]
机构
[1] Univ Lille, Claude Huriez Hosp, Dept Internal Med, Natl Reference Ctr Scleroderma, F-59037 Lille, France
[2] Univ Paris 11, Hop Antoine Beclere, AP HP, Clamart, France
[3] Orgametrie, Roubaix, France
[4] Grp Hosp St Joseph, Serv Med Vasc, Paris, France
[5] Hop Toulouse Purpan, Toulouse, France
[6] Hop Cardiol, F-59037 Lille, France
[7] Hop St Antoine, F-75571 Paris, France
[8] Hop Sud, Rennes, France
[9] Hop Cochin, F-75674 Paris, France
[10] Hop Nord, Grenoble, France
[11] Hop Hautepierre, Strasbourg, France
[12] Actel Pharmaceut France, Paris, France
[13] Hop Bretonneau, Tours, France
关键词
Systemic sclerosis; Survival; Pulmonary arterial hypertension; Pulmonary hypertension; PULMONARY ARTERIAL-HYPERTENSION; SCLERODERMA; CANCER; COHORT;
D O I
10.1093/rheumatology/ken488
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinrAIR-Sclrodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from investigators or French national death records. Causes of death were classified as SSc-related or otherwise. Data were censored at 37 months, time of death or loss to follow-up, whichever was earlier. Survival was estimated using the KaplanMeier method. Multivariate survival analyses were conducted using the Cox model. Results. In total, 546 patients were followed for a median duration of 37 months, representing 1547 patient-years. At baseline, the majority of patients were female, with lcSSc, mean age 54.9 13.0 years and mean duration of SSc of 8.8 8.1 years. In total, 47 patients died, giving a 3-year survival of 91.1 and cumulative mortality of 3.04 deaths per 100 patient-years; 17 deaths (32.2) resulted from pulmonary arterial hypertension (PAH) and eight (17.1) from cancer. Of the 47 patients with PAH at baseline, 20 died during follow-up, giving a 3-year survival of 56.3. In a multivariate analysis, PAH [hazard ratio (HR) 7.246], age at first symptom (HR 1.052), duration of SSc (HR 1.047 per year) and Rodnan skin score (per one point) (HR 1.045) were associated with increased mortality. Conclusion. This 3-year study observed survival and mortality estimates that were comparable with previous reports. PAH increased the HR for mortality in patients with SSc, justifying yearly echocardiographic screening.
引用
收藏
页码:304 / 308
页数:5
相关论文
共 15 条
  • [1] PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA)
    不详
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (05): : 581 - 590
  • [2] CLEMENTS PJ, 1993, J RHEUMATOL, V20, P1892
  • [3] Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis
    de Groote, P.
    Gressin, V.
    Hachulla, E.
    Carpentier, P.
    Guillevin, L.
    Kahan, A.
    Cabane, J.
    Frances, C.
    Lamblin, N.
    Diot, E.
    Patat, F.
    Sibilia, J.
    Petit, H.
    Cracowski, J-L
    Clerson, P.
    Humbert, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (01) : 31 - 36
  • [4] Derk CT, 2006, J RHEUMATOL, V33, P1113
  • [5] Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients
    Ferri, C
    Valentini, G
    Cozzi, F
    Sebastiani, M
    Michelassi, C
    La Montagna, G
    Bullo, A
    Cazzato, M
    Tirri, E
    Storino, F
    Giuggioli, D
    Cuomo, G
    Rosada, M
    Bombardieri, S
    Todesco, S
    Tirri, G
    [J]. MEDICINE, 2002, 81 (02) : 139 - 153
  • [6] Guidelines on diagnosis and treatment of pulmonary arterial hypertension -: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
    Galiè, N
    Torbicki, A
    Barst, R
    Dartevelle, P
    Haworth, S
    Higenbottam, T
    Olschewski, H
    Peacock, A
    Pietra, G
    Rubin, LJ
    Simonneau, G
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 (24) : 2243 - 2278
  • [7] Gibbs JSR, 2001, HEART, V86, pI1
  • [8] Pulmonary hypertension as a risk factor for death in patients with sickle cell disease
    Gladwin, MT
    Sachdev, V
    Jison, ML
    Shizukuda, Y
    Plehn, JF
    Minter, K
    Brown, B
    Coles, WA
    Nichols, JS
    Ernst, I
    Hunter, LA
    Blackwelder, WC
    Schechter, AN
    Rodgers, GP
    Castro, O
    Ognibene, FP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (09) : 886 - 895
  • [9] Early detection of pulmonary arterial hypertension in systemic sclerosis -: A French nationwide prospective multicenter study
    Hachulla, E
    Gressin, V
    Guillevin, L
    Carpentier, P
    Diot, E
    Sibilia, J
    Kahan, A
    Cabane, J
    Francès, C
    Launay, D
    Mouthon, L
    Allanore, Y
    Tiev, KP
    Clerson, P
    de Groote, P
    Humbert, M
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (12): : 3792 - 3800
  • [10] Risk of cancer in patients with scleroderma: a population based cohort study
    Hill, CL
    Nguyen, AM
    Roder, D
    Roberts-Thomson, P
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (08) : 728 - 731